AllSci News
Kazia Therapeutics acquires SETDB1 inhibitor platform from QIMR Berghofer
A preclinical bicyclic peptide targeting a disease-associated nuclear SETDB1 complex sits at the center of an in-licensing agreement announced April 13...
Eli Lilly acquires dual-payload ADC platform from CrossBridge Bio for up to USD 300m
Eli Lilly Acquires Dual-Payload ADC Platform for Up to USD 300 Million via CrossBridge Bio Deal
Mesoblast takes CAR-MSC platform license from Mayo Clinic spinout
Australia-based Mesoblast Limited (NASDAQ: MESO; ASX: MSB) has acquired an exclusive worldwide license to a patented chimeric antigen receptor technology...
Hengrui's obesity 'New Co.' Kailera Therapeutics targeting USD 500m Nasdaq IPO
Kailera Therapeutics (Nasdaq: KLRA) filed for an initial public offering of 33,333,334 shares of common stock at a price range of $14.00 to $16.00 per...
Kymera’s KT-621 STAT6 degrader receives FDA Fast Track designation for eosinophilic asthma
Kymera Therapeutics, Inc. (Nasdaq: KYMR), a clinical-stage biotech headquartered in Watertown, Massachusetts, announced that US FDA has granted Fast Track Designation to…
Molecular glue firm Neomorph picks up USD 100m Series B
San Diego-based Neomorph, Inc., a company focused on molecular glue degrader discovery, has closed a USD 100 million Series B financing round to advance its...
FDA approves Travere’s Filspari for focal segmental glomerulosclerosis in adults and pediatric patients
Travere Therapeutics announced that the US FDA has granted full approval to Filspari (sparsentan) to reduce proteinuria in adults and pediatric patients…
Adcendo closes USD 75m Series C financing to advance antibody-drug conjugate pipeline
Adcendo ApS, a Copenhagen-based clinical-stage biotechnology company developing antibody-drug conjugates for solid tumours, has closed an oversubscribed USD...
BioOra and Cincinnati Children's advance Atla-cel CAR-T therapy in pediatric B-cell acute lymphoblastic leukaemia
Atla-cel, an autologous CD19-directed CAR-T cell therapy developed by BioOra, is moving into paediatric clinical development after BioOra entered a...
Mayo Clinic invests in Sana Bio amid collaboration on cell therapy for type 1 diabetes
Sana Biotechnology, Inc. (Nasdaq: SANA), a Seattle-based cell engineering company, announced a strategic collaboration with Mayo Clinic to accelerate development of SC451,…
Spyre Therapeutics prices up USD 300m public offering
Waltham, Massachusetts-based Spyre Therapeutics, Inc. (NASDAQ: SYRE) has commenced an underwritten public offering of USD 300 million of common stock, with...
Novo Nordisk and OpenAI partner on enterprise-wide AI integration across drug discovery and operations
Novo Nordisk A/S (CPH: NOVO B), the Denmark-headquartered cardiometabolic and rare disease company, announced a strategic partnership with OpenAI to integrate the…
Renaissance Pharma’s daretabart GD2-targeted mAb gains FDA Fast Track for high-risk neuroblastoma
Renaissance Pharma Ltd, a wholly owned subsidiary of Essential Pharma and headquartered in the UK, announced that the US FDA has granted…
Spyre's SPY001 meets primary endpoint in Phase II ulcerative colitis induction trial
Spyre Therapeutics (Nasdaq: SYRE) reported that SPY001, its extended half-life anti-α4β7 antibody, met the primary endpoint in the open-label Part A of the...
GSK's B7-H4 ADC set for 5 Phase III trials in gynecological cancers after strong Phase I
GSK (LSE/NYSE: GSK) reported Phase I data for mocertatug rezetecan, a B7-H4-targeted antibody-drug conjugate, showing confirmed objective response rates of...
The AllSci Brief
Free, systematic R&D and deal news. Daily.